Lipidic α-synuclein fibrils catalyze the formation of pathological mature fibrils

Lipidic α-synuclein fibrils catalyze mature fibril formation by heterogeneous primary nucleation, lowering the activation energy barrier versus lipid-independent nucleation.

• Why it matters: Synucleinopathies like Parkinson’s disease involve α-synuclein amyloid formation, but how lipid–protein intermediates control the transition to mature, Lewy-body–like fibrils is unclear.
• What they did: The study combines experiments with kinetic theory to analyze how lipids and lipidic fibrils shape mature fibril kinetics, and tests ambroxol, which suppresses lipidic fibrils.
• The result: Mature fibril elongation is limited by monomer dissociation from metastable lipidic fibrils, consistent with Ostwald’s Rule of Stages, and ambroxol shifts aggregation to the slow lipid-independent pathway.

AI summary of the abstract · may contain errors · not medical advice · read the paper.